Author Question: Drugs that inactivate monoamine oxidase would be expected to A) reduce dopamine levels within the ... (Read 82 times)

sjones

  • Hero Member
  • *****
  • Posts: 520
Drugs that inactivate monoamine oxidase would be expected to
 
  A) reduce dopamine levels within the blood.
  B) elevate acetylcholine levels within the muscles.
  C) reduce serotonin levels in the synaptic cleft.
  D) cause the release of serotonin into the synaptic cleft.
  E) increase dopamine levels within neurons.

Question 2

Deprenyl may delay the progression of symptoms in Parkinson's disease because this drug
 
  A) facilitates monoamine oxidase-A.
  B) reduces dopamine activity in the synapse.
  C) inhibits monoamine oxidase-B.
  D) acts on dopamine autoreceptors.
  E) is a potent D1/D2 agonist.



Jayson

  • Sr. Member
  • ****
  • Posts: 350
Answer to Question 1

Answer: E
Rationale: Drugs that inactivate monoamine oxidase would be expected to increase dopamine levels within neurons.

Answer to Question 2

Answer: C
Rationale: Deprenyl may delay the progression of symptoms in Parkinson's disease because this drug inhibits monoamine oxidase-B.



Related Topics

Need homework help now?

Ask unlimited questions for free

Ask a Question
 

Did you know?

To maintain good kidney function, you should drink at least 3 quarts of water daily. Water dilutes urine and helps prevent concentrations of salts and minerals that can lead to kidney stone formation. Chronic dehydration is a major contributor to the development of kidney stones.

Did you know?

Complications of influenza include: bacterial pneumonia, ear and sinus infections, dehydration, and worsening of chronic conditions such as asthma, congestive heart failure, or diabetes.

Did you know?

After a vasectomy, it takes about 12 ejaculations to clear out sperm that were already beyond the blocked area.

Did you know?

In women, pharmacodynamic differences include increased sensitivity to (and increased effectiveness of) beta-blockers, opioids, selective serotonin reuptake inhibitors, and typical antipsychotics.

Did you know?

Despite claims by manufacturers, the supplement known as Ginkgo biloba was shown in a study of more than 3,000 participants to be ineffective in reducing development of dementia and Alzheimer’s disease in older people.

For a complete list of videos, visit our video library